Gain Therapeutics, Inc.
SEC CIK 1819411 · GANX · last insider filing 2026-03-26
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Mack Gene | Director · Chief Financial Officer | filed 2024 - 2026 |
| Goldstein DOV A MD | Director | filed 2021 - 2025 |
| Hasler Hans Peter | Director | filed 2021 - 2025 |
| Richman Eric I | Director · Chief Executive Officer | filed 2021 - 2025 |
| Riley Jeffrey Scott | Director | filed 2021 - 2025 |
| Melincoff Gwen A | Director | filed 2021 - 2025 |
| Nicaise Claude | Director | filed 2021 - 2025 |
| Islam Khalid | Director · Executive Chairman | filed 2021 - 2025 |
| Alder Matthias | Director · Chief Operating Officer | filed 2021 - 2024 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Fuggetta Gianluca | See Remark | filed 2022 - 2026 |
| Ballantyne Charles Evan | Chief Financial Officer | filed 2023 - 2023 |
| Calabrese Salvatore | Chief Financial Officer | filed 2021 - 2023 |
| Bellotto Manolo | President and General Manager | filed 2021 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.